Home / TRAIL R2/TNFRSF10B / Human TRAIL R2/TNFRSF10B Antibody

Human TRAIL R2/TNFRSF10B Antibody

Catalog #: AF631
32 Citations Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
AF631
AF631-SP
Detection of Human TRAIL R2/TNFRSF10B by Western Blot.
1 Image
Product Details
Citations (32)
FAQs
Supplemental Products
Reviews
Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human TRAIL R2/TNFRSF10B Antibody Summary

Species Reactivity
Human
Specificity
Detects human TRAIL R2/TNFRSF10B in direct ELISAs and Western blots.
Source
Polyclonal Goat IgG
Purification
Antigen Affinity-purified
Immunogen
Mouse myeloma cell line NS0-derived recombinant human TRAIL R2/TNFRSF10B
Ala54-Glu182
Accession # Q6FH58
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Western Blot
1 µg/mL
See below
Agonist Activity
Measured by its ability to induce apoptosis on Jurkat human acute T cell leukemia cells. The ED50 for this effect is typically 7.00 - 70.0 ng/mL.
 

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot Detection of Human TRAIL R2/TNFRSF10B antibody by Western Blot. View Larger

Detection of Human TRAIL R2/TNFRSF10B by Western Blot. Western blot shows lysates of HepG2 human hepatocellular carcinoma cell line. PVDF membrane was probed with 1 µg/mL of Human TRAIL R2/TNFRSF10B Antigen Affinity-purified Polyclonal Antibody (Catalog # AF631) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (HAF019). A specific band was detected for TRAIL R2/TNFRSF10B at approximately 45 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS.
Loading...
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: TRAIL R2/TNFRSF10B

Human TRAIL R2, also called DR5 and TRICK 2 is a type 1, TNF R family, membrane protein which is a receptor for TRAIL (APO2 ligand). In the new TNF superfamily nomenclature, TRAIL R2 is referred to as TNFRSF10B. TRAIL R2 cDNA encodes a 440 amino acid residue precursor protein containing extracellular cysteine-rich domains, a transmembrane domain and a cytoplasmic death domain. Among TNF receptor family proteins, TRAIL R2 is most closely related to TRAIL R1/DR4, sharing 55% amino acid sequence identity. Binding of trimeric TRAIL to TRAIL R2 induces apoptosis. The induction of apoptosis likely requires oligomerization of the receptor. The human TRAIL R2/Fc chimera neutralizes the ability of TRAIL to induce apoptosis. Besides TRAIL R2, an additional TRAIL R1/DR4, which tranduces apoptosis signaling, and two TRAIL decoy receptors, which antagonize TRAIL-induced apoptosis, have been reported.

References
  1. Chaudhary, P.M. et al. (1997) Immunity 7:821.
  2. Walczak, H. et al. (1997) EMBO J. 16:5386.
  3. Golstein, P. (1997) Curr. Biol. 7:R750.
Long Name
TRAIL Receptor 2
Entrez Gene IDs
8795 (Human); 21933 (Mouse)
Alternate Names
CD262 antigen; CD262; death domain containing receptor for TRAIL/Apo-2L; Death receptor 5; DR5; DR5TRICK2B; Fas-like protein; KILLER/DR5; KILLERapoptosis inducing protein TRICK2A/2B; TNF-related apoptosis-inducing ligand receptor 2; TNFRSF10B; TRAIL R2; TRAIL receptor 2; TRAILR2; TRAIL-R2apoptosis inducing receptor TRAIL-R2; TRAILR2cytotoxic TRAIL receptor-2; TRICK2; TRICK2A; TRICKB; tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9; ZTNFR9

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Citations for Human TRAIL R2/TNFRSF10B Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

32 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Soluble Fas ligand drives autoantibody-induced arthritis by binding to DR5/TRAIL-R2
    Authors: Dongjin Jeong, Hye Sung Kim, Hye Young Kim, Min Jueng Kang, Hyeryeon Jung, Yumi Oh et al.
    eLife
  2. Off-Target Lapatinib Activity Sensitizes Colon Cancer Cells Through TRAIL Death Receptor Up-Regulation
    Authors: Nathan G. Dolloff, Patrick A. Mayes, Lori S. Hart, David T. Dicker, Robin Humphreys, Wafik S. El-Deiry
    Science Translational Medicine
  3. Limiting glutamine utilization activates a GCN2/TRAIL-R2/Caspase-8 apoptotic pathway in glutamine-addicted tumor cells
    Authors: R Yerbes, R Mora-Molin, FJ Fernández-, L Hiraldo, A López-Riva, C Palacios
    Cell Death & Disease, 2022-10-27;13(10):906.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  4. cFLIP downregulation is an early event required for endoplasmic reticulum stress-induced apoptosis in tumor cells
    Authors: R Mora-Molin, D Stöhr, M Rehm, A López-Riva
    Cell Death & Disease, 2022-02-03;13(2):111.
    Species: Human
    Sample Types: Cell Lysates, Whole Cells
    Applications: Flow Cytometry, Western Blot
  5. Cytotoxic Efficacy and Resistance Mechanism of a TRAIL and VEGFA-Peptide Fusion Protein in Colorectal Cancer Models
    Authors: M Kopczynski, M Statkiewic, M Cybulska, U Kuklinska, K Unrug-Biel, Z Sandowska-, A Grochowska, M Gajewska, M Kulecka, J Ostrowski, M Mikula
    International Journal of Molecular Sciences, 2021-03-19;22(6):.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  6. Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas
    Authors: Y An, J Jeon, L Sun, A Derakhshan, J Chen, S Carlson, H Cheng, C Silvin, X Yang, C Van Waes, Z Chen
    Scientific Reports, 2021-03-18;11(1):6392.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  7. Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells
    Authors: Y Shlyakhtin, V Pavet, H Gronemeyer
    Cell Death Dis, 2017-08-31;8(8):e3025.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Immunoprecipitation
  8. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma
    Authors: V Liapis, A Zysk, M DeNichilo, I Zinonos, S Hay, V Panagopoul, A Shoubridge, C Difelice, V Ponomarev, W Ingman, GJ Atkins, DM Findlay, ACW Zannettino, A Evdokiou
    Cancer Med, 2017-08-10;0(0):.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  9. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
    Authors: Kim, Seong Mu, Woo, Ji Sun, Jeong, Chang Hy, Ryu, Chung He, Jang, Jae-Deog, Jeun, Sin-Soo
    Stem Cells Transl Med, 2014-01-16;3(2):172-82.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  10. Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells.
    Authors: Park SJ, Sohn HY, Yoon J, Park SI
    Cell. Signal., 2009-05-24;21(10):1495-503.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  11. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
    Authors: Park SJ, Kim MJ, Kim HB, Kang CD, Kim SH
    Biochem. J., 2009-04-28;420(1):73-81.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry, Neutralization
  12. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
    Authors: Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, Kim SH
    Biochem. Pharmacol., 2009-01-24;77(8):1328-36.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  13. Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells.
    Authors: Festuccia C, Gravina GL, D'Alessandro AM, Millimaggi D, Di Rocco C, Dolo V, Ricevuto E, Vicentini C, Bologna M
    Int. J. Oncol., 2008-08-01;33(2):381-8.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  14. TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5.
    Authors: Wu CH, Kao CH, Safa AR
    Hum. Gene Ther., 2008-07-01;19(7):731-43.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  15. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation.
    Authors: Kim EH, Yoon MJ, Kim SU, Kwon TK, Sohn S, Choi KS
    Cancer Res., 2008-01-01;68(1):266-75.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  16. Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.
    Authors: Zopf S, Neureiter D, Bouralexis S, Abt T, Glaser KB, Okamoto K, Ganslmayer M, Hahn EG, Herold C, Ocker M
    Int. J. Oncol., 2007-12-01;31(6):1391-402.
    Species: Human
    Sample Types: Cell Lysates, Whole Cells
    Applications: Functional Assay, Western Blot
  17. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
    Authors: Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR
    Biochem. Pharmacol., 2006-05-04;72(3):293-307.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  18. Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3.
    Authors: Lane D, Cote M, Grondin R, Couture MC, Piche A
    Mol. Cancer Ther., 2006-03-01;5(3):509-21.
    Species: Human
    Sample Types: Whole Cells
    Applications: Western Blot
  19. Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis.
    Authors: Roux S, Lambert-Comeau P, Saint-Pierre C, Lepine M, Sawan B, Parent JL
    Biochem. Biophys. Res. Commun., 2005-07-22;333(1):42-50.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  20. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt.
    Authors: Morel J, Audo R, Hahne M, Combe B
    J. Biol. Chem., 2005-01-31;280(16):15709-18.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  21. Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death.
    Authors: Ricci-Vitiani L, Pedini F, Mollinari C, Condorelli G, Bonci D, Bez A, Colombo A, Parati E, Peschle C, De Maria R
    J. Exp. Med., 2004-11-15;200(10):1257-66.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  22. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1).
    Authors: Chopin V, Slomianny C, Hondermarck H, Le Bourhis X
    Exp. Cell Res., 2004-08-15;298(2):560-73.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  23. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site.
    Authors: Ruiz de Almodovar C, Ruiz-Ruiz C, Rodriguez A, Ortiz-Ferron G, Redondo JM, Lopez-Rivas A
    J. Biol. Chem., 2003-11-17;279(6):4093-101.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  24. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells.
    Authors: Secchiero P, Milani D, Gonelli A, Melloni E, Campioni D, Gibellini D, Capitani S, Zauli G
    J. Leukoc. Biol., 2003-08-01;74(2):223-32.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  25. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines.
    Authors: Mouzakiti A, Packham G
    Br. J. Haematol., 2003-07-01;122(1):61-9.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  26. An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.
    Authors: Voelkel-Johnson C
    Cancer Biol. Ther., 2003-05-01;2(3):283-90.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  27. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells.
    Authors: Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, Rana R, Vitale M, Secchiero P
    Circ. Res., 2003-03-20;92(7):732-40.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  28. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation.
    Authors: Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S, Miyazoe S, Nakagawa Y, Ishikawa H, Hamasaki K, Nakata K, Ishii N, Eguchi K
    Oncogene, 2003-03-20;22(11):1653-62.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  29. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
    Authors: Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC
    Oncogene, 2002-08-22;21(37):5673-83.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  30. Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells.
    Authors: Bretz JD, Mezosi E, Giordano TJ, Gauger PG, Thompson NW, Baker JR
    Cell Death Differ., 2002-03-01;9(3):274-86.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry, Functional Assay, Western Blot
  31. Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells
    Authors: V Pavet, Y Shlyakhtina, T He, D G Ceschin, P Kohonen, M Perälä et al.
    Cell Death & Disease
  32. Combination treatment with VPA and MSCs‑TRAIL could increase anti‑tumor effects against intracranial glioma
    Authors: Soon A. Park, Hye Rim Han, Stephen Ahn, Chung Heon Ryu, Sin‑Soo Jeun
    Oncology Reports

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human TRAIL R2/TNFRSF10B Antibody

There are currently no reviews for this product. Be the first to review Human TRAIL R2/TNFRSF10B Antibody and earn rewards!

Have you used Human TRAIL R2/TNFRSF10B Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review